Welcome to the Division of Pulmonary, Allergy & Critical Care Medicine
Pulmonary, Allergy & Critical Care Medicine
The Division of Pulmonary, Allergy, and Critical Care Medicine (PACCM) is comprised of a team of outstanding clinicians, scientists, and scholars dedicated to improving the lives of patients with serious lung and allergic diseases and those who are critically ill. Read more
PACCM Diversity Statement:
Stanford PACCM supports the Black Lives Matter movement and is committed to fighting racial injustice in our community and country. We recognize institutionalized racism as a public health crisis, and stand alongside all who are calling for sweeping and transformative changes. Our division stands firm in supporting diversity in the many forms it takes and is dedicated to promoting the health of our patients and the communities we serve. We additionally recognize the disparities that persist within the halls of academic medicine and will work hard to enable every member of our faculty, fellowship, residency, and student body to find success. Our division stands united in taking the actions needed to build a more diverse and inclusive environment for our patients, trainees, and faculty.
PACCM is one division of a larger Department of Medicine (DOM). The Stanford DOM is fully committed to supporting diversity and inclusion.
About our Fellowship Program
Welcome to the Stanford Pulmonary, Allergy and Critical Care Medicine Fellowship. We offer a 3-year ACGME accredited fellowship designed to provide outstanding clinical and research training in an intellectually vibrant and highly supportive learning environment. Our fellowship’s four distinct tracks are structured to offer trainees experiences that align with their unique career goals. We also offer an additional 4th year of subspecialty training in Lung Transplantation, Pulmonary Hypertension and Sleep Medicine which fellows can apply for in their third year.
All fellows receive 18-20 months of clinical training in Pulmonary & Critical Care Medicine with core rotations at Stanford University Hospital, the Santa Clara Valley Medical Center, and the Palo Alto VA Health Care System. By rotating at these hospitals with distinct patient populations, fellows are exposed to a wide breadth of disease states and pathology. Our elective courses provide the opportunity for the additional in-depth study of specific areas of interest. Our fellows are also provided ample time to explore outstanding research opportunities at Stanford. Thank you for your interest in our fellowship program and for exploring our website. Please don't hesitate to contact us for further information. We are currently recruiting fellows for the class of 2020, as part of the NRMP match.
Events and Announcements
December 3, 2020
Welcome to the Stanford PCCM Class of 2024!
The Stanford Pulmonary, Allergy, & Critical Care Medicine Division is thrilled to introduce the members of our incoming class of PCCM Fellows, starting July 2021!
Dr. Solmaz Afshar, Yale
Dr. Landy Luna, University of Miami chief
Dr. Manoj Maddali, UCSF
Dr. Jason Melehani, Stanford
Dr. Andrew Moore, Stanford chief
Dr. Shaun Pienkos, Stanford
Dr. Maya Viavant, Cornell chief
We could not be more proud of our incoming class of fellows and please join us in welcoming them to the Stanford family!
November 24, 2020
It is with great pleasure to announce that Dr. Sharon Chinthrajah has won a national search for a Faculty Position focusing on clinical research in allergy and asthma at Stanford. As an Associate Professor in the Medical Center Line track, Sharon is also an endowed faculty from the Crown Family who established herself as a physician-scientist investigating immune mechanisms in food allergy and asthma. She is the Director of the Clinical Translational Research Unit of the Sean N. Parker Center for Allergy and Asthma Research where she leads the team to conduct novel and impactful Phase 1-3 studies in food allergy, asthma, allergic rhinitis, and atopic dermatitis. She currently oversees over 26 active clinical trials and is funded by the NIH in the overlapping diseases of food allergy, asthma, allergic rhinitis, eczema, and eosinophilic esophagitis. She investigates immune dysregulation and is licensed in both Pulmonary/Critical Care and Allergy/immunology.
Nominated by Dean Minor and Bob Harrington, Sharon was also selected as one of the top clinical research projects by The Clinical Research Forum in 2020 for her study “Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomized, double-blind, placebo-controlled, phase 2 study”. This study was chosen from an impressive field of application and extremely qualified research programs.
November 16, 2020
We are thrilled to announce a new leadership role for Dr. Tushar Desai who will serve as the Stanford PACCM Director of Translational Lung Biology. As most of you know, Tushar is an emerging international leader in basic and translational lung biology and has become a highly effective mentor and guiding force for academic endeavors.
In this role, Tushar will continue to co-organize the Divisional PACCM Grand Rounds series (with Angela Rogers) and engage the trainees in the Pulmonary Biology T32 seminar series to provide scientific mentoring. He will also launch a regular series for fellows and instructors engaged in lab research to foster a community in which topical workshops and seminars will help facilitate their scientific and career development.
Tushar would love to meet all trainees and junior faculty interested in careers centered on exploring lung health and disease - so please also feel free to reach out to him on your own to connect.
November 16, 2020
PACCM is playing a major role on the pandemic frontline. The most recent issue of Stanford Medicine features a great story about interdisciplinary collaboration in the Medical Intensive Care Unit. Dr. Ann Weinacker is the new Medical Director of this Unit. The story prominently features Drs. Angela Rogers and Javier Lorenzo (Anesthesia).
Urgency for collaboration became clear. Chaired by Angela Rogers, MD, the Stanford COVID-19 critical care task force met three times a week at first to hash out the best-practice guidelines. At its peak during those early days, staff members were caring for 10 to 15 patients and preparing for the possibility of a sudden increase along the lines of what hit New York and Boston.
October 5, 2020
A big congratulations to Dr. Andrea Jonas for her first author articles regarding her recent work in vaping related lung disease! Her first article was published in Chest this month: Chest EVALI Systematic Review: https://authors.elsevier.com/a/1bs6f2p-k%7EwDP along with a Chest Vaping Podcast: https://journal.chestnet.org/podcast-archive-2020. She also reviewed and then wrote an editorial on lipid laden macrophages in vaping related lung injury as well: EbioMedicine Lancet Editorial: https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(20)30386-8/fulltext. Andrea is doing a great job under Dr. Rishi Raj’s mentorship.
September 29, 2020
(From Reddy, Sumathi "Four Different Family Members, Four Different Covid-19 Outcomes", Wall Street Journal https://apple.news/A91FwLlDPR1i10egCz2THGw)
Dr. Kari Nadeau of Stanford and Columbia researchers study why people, even in the same family, have different coronavirus symptoms.
The Ruspini family in Sunnyvale, Calif., went down like dominoes. One by one, they all got the coronavirus in early April, but with different symptoms and recovery trajectories.
Diego Ruspini, a 53-year-old computer scientist with a history of asthma, was hospitalized for a week in early April, and coped with respiratory issues and fatigue until August.
His wife, Connie Lares, a 48-year-old medical interpreter at Stanford Children’s Hospital, had a couple of weeks of low-grade fever, body aches, diarrhea and hot flashes. By June she felt well enough to hike a 14,500-foot mountain.
Their 17-year-old daughter, Natalia, was hardly able to eat for months, and dealt with brain fog and fatigue. And their 12-year-old son, Santiago, had no symptoms except for an increased appetite and low-grade fever for a few days, despite a congenital heart condition.
One of the biggest mysteries of the virus that causes Covid-19 is why it leads to such different experiences for the people it strikes. While some severe outcomes can be explained by people more at risk of serious illness—such as the elderly and those with chronic conditions—other outcomes have left doctors and researchers stumped, particularly the subset of Covid-19 patients with persistent symptoms, who often refer to themselves as long-haulers or long-
Several studies—including at Columbia University, Stanford University School of Medicine, and the University of California, San Francisco—are trying to better understand the different reactions to the same virus.
“The thing that has really stood out to me the most about this viral infection is that it’s really remarkable how much variability there is on the recovery end,” says Michael Peluso, a clinical fellow in the division of HIV, infectious diseases, and global medicine at UCSF, and a member of a team working on the LIINC (Long-term Impact of Infection with Novel Coronavirus) study.
The Ruspini family is part of a Stanford Medicine study—called The Long Term Immunity(LTI) study—looking at the immune response and post-Covid health of about 200
participants. The study includes 40 children, 20 pregnant women, as well as couples and families. About 30% of participants were hospitalized due to Covid-19.
The participants’ symptoms are varied and can’t all be explained by genetics, says Kari Nadeau, a professor of medicine and pediatrics at Stanford University and director of its Sean N. Parker Center for Allergy and Asthma Research, who is overseeing the study. “Even within one family who get the same strain of the virus at the same time and have the same underlying genetics, the symptoms that people are showing can be different,” says Dr. Nadeau.
September 16, 2020
Dr. Angela Rogers, who co-directs the Stanford IM Program and leads our PACCM Fellowship and as well as COVID-19 ICU efforts, has just been awarded a $3M NIH R01 grant evaluating patients with ARDS in the ICU. The grant focuses on the molecular characterization of pulmonary edema - using the fluid that is readily available in endotracheal aspirates of mechanically-ventilated patients as a window for understanding on the pathogenic processes at play in injured lungs.
We always expect great things of Angela, and so aren't surprised by this great success. It's worth noting, though, that getting an R01 in critical care studies is particularly challenging for young investigators. This is because of the multi-institutional nature of the work that really depends on cooperative efforts of the clinical researchers - often hard to achieve for junior faculty. In this regard, Angela has been able to effectively work with great talent at UCSF and Vanderbilt to forge such an impactful proposal. Such efforts help further lift the national profile of Stanford's amazing MICU program.
September 15, 2020
We are excited to announce that David Condon has been selected as a 2020 TRAM scholar by the Department of Medicine for his work entitled "The role of LITAF in the pathogenesis of pulmonary hypertension".
TRAM scholarships are awarded to 10 highly promising fellows and early career faculty members with clinical and translational research projects judged to have high potential of yielding transformative results.
Over the next two years, David will carry out translational studies that will establish the contribution of the immunomodulatory protein LITAF on the initiation and progression of vascular inflammatory responses in the lung.
September 9, 2020
Understanding Emphysema – The Role of HIF-2α
Pulmonary diseases like emphysema are the third leading cause of death in the US and the fourth leading cause worldwide. Emphysema occurs when air sacs in the lungs are damaged; such as after exposure to smoke, air pollution, or chemical fumes and dust. As emphysema gets worse, the walls of the air sacs weaken and rupture, creating larger air spaces inside the lungs. Having larger air spaces means the lungs have less opportunity to take up oxygen and therefore less oxygen enters the blood stream. The damaged air sacs also make it harder for the lungs to cycle out old, oxygen-depleted air for new, oxygen-rich air. Despite emphysema’s broad prevalence and severe outcomes, current treatment methods target symptom relief – not prevention or reversal of the disease itself.
Smoke inhalation, one of the primary causes of emphysema, has been shown to cause a decrease in the expression of a particular protein that is enriched in the lungs: HIF-2α. HIF proteins are known to be involved in oxygen processing both in low-oxygen environments, where they trigger the expression of genes that improve oxygen uptake efficiency, as well as in normal oxygen environments, where they help maintain air sac architecture and promote cell survival. Given the facts that 1) smoke inhalation triggers a decrease in HIF-2α, and 2) HIF-2α has a known important role in oxygen processing and maintaining lung air sac architecture, a group of scientists including first author Shravani Pasupneti, MD, senior authors, Xinguo Jiang, MD, PHD and Mark Nicolls, MD of Stanford University and Nobel-Laureate Gregg Semenza, MD, PhD of Johns Hopkins, chose to investigate whether changes in HIF-2α levels could be directly responsible for emphysema.
In their study, recently published in the American Journal of Respiratory and Critical Care Medicine, the authors used genetic manipulations to both decrease and increase HIF-2α levels. When they decreased HIF-2α levels in mice, they were able to recreate the lung pathology of emphysema (e.g. air sac enlargement). They also showed that this effect was specific to HIF-2α, because decreasing levels of a similar protein, HIF1α, did not cause lung-related dysfunction. Not only did they show that lack of HIF-2α causes emphysema, but they also demonstrated that the presence of HIF-2α is actually protective. Increasing levels of HIF-2α in mice prevented the animals from the pathological air sac enlargement and cell death that is typical in emphysema. Combined, Pasupneti et al’s results show that loss of HIF-2α function could be directly responsible for the symptoms seen in individuals with emphysema. Identifying ways to preserve HIF-2α function is therefore a promising opportunity for therapies that would limit emphysema progression – or even prevent emphysema in at-risk patients.
An editorial of this study by Emma Hodson MD, PHD and 2019 Nobel-laureate Peter Ratcliffe, MD was published alongside this manuscript and provides further context for the authors’ results.
Other Stanford Cardiovascular Institute-affiliated authors include Wen Tian, Allen B. Tu, Petra Dahms, Eric Granucci, Menglan Xiang, and Eugene Butcher.
July 29, 2020
Congrats to Angela Rogers and her Stanford team including first author Jenny Wilson (ED/CCM), Joe Levitt, Catherine Blish (ID) and Holden Maecker (Stanford Human Immune Monitoring Center) - for a new paper in JCI Insight showing that the inflammatory cytokine profiles are similar in severe COVID-19, ARDS and sepsis. The failure of Phase 3 studies using immunosuppressive therapies targeting specific cytokines could be explained by these results. https://insight.jci.org/articles/view/140289
This paper is an important contribution to the COVID-19 literature on inflammation and can be considered alongside a new foundational study published in the journal Nature which considers how a maladapted immune response associates with severe COVID-19 outcomes and how early immune signatures may correlate with divergent disease trajectories. https://www.nature.com/articles/s41586-020-2588-y
These new studies are progressively informing clinical researchers on best approaches for therapeutic drug design in the pandemic.
Another great example of how interdisciplinary research can work so well at Stanford!
June 26, 2020
The Stanford PCCM and CCM Fellows from the graduating Class of 2020 have jointly come together to support disadvantaged populations who have been disproportionately affected by the pandemic.
The fellows have banded together to support organizations taking action against racism and to empower young people of color in poor communities. We are so proud and humbled by their leadership on this paramount social issue. We know that they are immensely talented individuals, and we have confidence that they will be launching their careers with strong hearts, noble minds and great promise.
For more information about their effort and an opportunity to financially contribute, please go to this link.
June 24, 2020
Congratulations to Andrew Sweatt MD, new recipient of an NIH K23 Award! Dr. Sweatt is a Clinical Assistant Professor with expertise in pulmonary hypertension.
He recently authored an already highly-cited Circulation Research study which effectively illustrates how machine-learning approaches can be used to organize complicated data sets (in this case, inflammatory biomarkers) to classify pulmonary hypertension phenotypes in an unprecedented manner. By using artificial intelligence methodologies, new discoveries are rapidly being made, and Stanford, a pioneering site for the development of this field, has been a wonderful launching pad for Andy's career.
For this training award, Dr. Roham Zamanian will be serving as his Mentor. Obtaining a K-award is an important early step for faculty developing research careers. Challenging to obtain and a true rite of passage.
June 23, 2020
Please congratulate and give a warm welcome to Maya Kasowski MD, PhD who will be joining us on July 1st as the new Sean N. Parker Faculty Scholar and Assistant Professor in the Sean N. Parker Center for Allergy and Asthma Research, Division of Pulmonary, Allergy, Critical Care and with secondary appointment in Dept of Pathology and courtesy appointment in Dept of Genetics. Dr. Kasowski has published in Science, Cell, and Nature, and other high impact journals and will lead her laboratory in the BMI building. Dr. Kasowski is a clinical pathologist and genomicist joining our Center to study allergic disorders. Dr. Kasowski will work with biospecimens from our clinical trials to investigate links between genetic variants and immune responses in patients undergoing oral immunotherapy.
Maya earned her MD from Yale University School of Medicine and her PhD from Yale University. Her PhD was in Molecular, Cellular, and Developmental Biology in Dr. Michael Snyder's lab. She completed her residency in pathology and her post-doctoral fellowship in genetics, both at Stanford University. She recently received a KL2 Mentored Career Development Award for two years of research funded by the National Institutes of Health (NIH) and the Stanford Clinical Translational Science Award (CTSA) Program. Dr. Kasowski is assistant director of the Molecular Pathology Core, a laboratory in pathology dedicated to translating scientific discovery at Stanford into new clinical tests.
Maya grew up on a horse farm in the Philadelphia area and when she's not in the lab enjoys going for hikes with her three young children.
June 22, 2020
We are proud to announce three MICU attendings who will form the PACCM representation for the newly-formed Yellow Team. The three new MICU attendings are:
- Pedram Fatehi (Nephrology/PACCM)
- Harmeet Bedi (PACCM)
- Andrea Jonas (PACCM)
The Yellow Team is an attending-only service (no residents or fellows yet) that is being created in response to rising MICU patient volumes. We expect that, in time, it will become a fully-staffed group like the Blue and Green Teams.
In PACCM, we have >15 critically-care boarded MDs to consider. Arthur Sung and I rated a number of parameters and arrived at the same three individuals. We appreciate that these are highly-sought after positions and took quite a bit of care with this process. We turned to Paul Mohabir who enthusiastically agreed with the lineup. Paul has been instrumental in working with the Departments of Anesthesia and Emergency Medicine to design the newly-minted Yellow Team.
Pedram Fatehi (https://profiles.stanford.edu/pedram-fatehi) has been a fixture in the Stanford Critical Care world for many years. After Medicine/Nephrology training at Columbia and CCM fellowship at UCSF, he was on faculty at UCSF and in critical care practice for five years before joining the Stanford faculty in 2014. His dedication to intensive care unit has been inspiring. Since 2017, he has served on the Stanford ICU Professional Practice Evaluation Committee and the Stanford ICU Continuing Quality Improvement Committee. An avid educator, Pedram has won the Nephrology Teaching Award for the past two years. He is an amazing doctor, a passionate academic and warm colleague with a secondary appointment in our Division.
Harmeet Bedi (https://profiles.stanford.edu/harmeet-bedi) is a beloved clinical educator (Winner of the 2018 PACCM Teaching Award), skilled interventional pulmonologist and intensivist. He also won the Mentorship Award for the Stanford Biodesign Fellowship Program two years in a row (2017 and 2018). He is an exceedingly well-trained proceduralist and clinician who already has a strong working relationship with our colleagues in Cardiovascular Anesthesia.
Andrea Jonas (https://profiles.stanford.edu/199287) is a graduating Chief PACCM fellow who has already distinguished herself as an emerging leader. A graduate of Harvard (Chemistry and Physics), followed by medical school and IM residency at Johns Hopkins where she developed a strong interest in critical care medicine. She is already signed up for Valley Care MICU service, which, like the Yellow Team, is an attending-only service. She is becoming the new Associate Program Director of the PCCM Fellowship in the 2020-2021 academic year, joining Angela Rogers as the new PCCM Fellowship Program Director. Andrea has a special interest in Palliative Care and ICU Survival Cohorts.
We feel honored and proud to have such distinguished individuals in our midst.
May 22, 2020
The American Journal of Respiratory and Critical Care Medicine (our field's flagship journal, now with an IF of 16.5) published their fascinating case report detailing the outpatient management of a patient with concomitant idiopathic pulmonary arterial hypertension (iPAH) and COVID-19 disease using inhaled nitric oxide (iNO). https://www-atsjournals-org.laneproxy.stanford.edu/doi/abs/10.1164/rccm.202004-0937LE
The journal has been flooded with hundreds of COVID-19 manuscript submissions - raising the question about why this particular report 'made the cut'. In an accompanying Editorial, which came online today, international PAH authority, Mark Gladwin M.D., described the potential ramifications of the study - that this report confirms the rationale of iNO as a therapeutic agent for COVID-19 patients. https://www.atsjournals.org/doi/pdf/10.1164/rccm.202005-1906ED.
To this end, Roham is now leading a multicenter trial, a randomized open-label study of supportive therapy with or without iNO in COVID-19 patients (the COVIDiNO Study). A great example of how we can use a single interesting case report to build a theory of disease. Congrats again to Vinicio, Ken, and Roham for their efforts in this challenging and internationally-focused arena!
April 29, 2020
We want to give a tremendous shout-out and congratulations to our chief fellow, Dr. Andrea Jonas. As part of her work with Clinical Excellence Research Center this year, she co-authored a perspectives piece published in the NEJM, entitled " Covid-19 and Health Care’s Digital Revolution" . https://www.nejm.org/doi/full/10.1056/NEJMp2005835?query=RP
Covid-19 and Health Care’s Digital Revolution In the face of the Covid-19 pandemic, Americans are waking up to the limitations of their analogue health care system. It seems clear that we need ...
April 28, 2020
From the AAP site: "The Association of American Physicians is a nonprofit, professional organization founded in 1885 by seven physicians, including Dr. William Osler and Dr. William Henry Welch, for “the advancement of scientific and practical medicine. "
"The goals of its members include the pursuit of medical knowledge, and the advancement through experimentation and discovery of basic and clinical science and their application to clinical medicine. Each year, individuals having attained excellence in achieving these goals, are recognized by nomination for membership by the Council of the Association. Their election gives them the opportunity to share their scientific discoveries and contributions with their colleagues at the annual meeting."
Dr. Nadeau was nominated by George Q. Daley, Dean of Harvard Medical School, and Dr. Nicolls, by Gregg Semenza, Professor of Genetic Medicine and winner of the 2019 Nobel Prize in Physiology or Medicine.
The AAP is known as the "Old Turks" to be compared with the "Young Turks" of the American Society of Clinical Investigation (ASCI) which was founded in 1908. As we previously announced, Tushar Desai and Vinicio de Jesus Perez were elected into ASCI this year - so all round, a banner year for PACCM!
April 17, 2020
There is so much work going on at the bedside and in the research arena to address our world-wide pandemic at Stanford. Our own Ryan Van Wert M.D., the Associate Director of the Biodesign Faculty Fellowship who was instrumental in the development of a prototype for a new scaled-down ventilator with the support of the Chan Zuckerberg Biohub.
An effort to design and build new, simplified ventilators for patients with severe cases of COVID-19 is being led by researchers at Stanford. Severely ill patients with COVID-19, whose lungs have been damaged due to the virus, require ventilators — machines that mechanically “breathe” for them ...
The aim of this project is to replenish ventilator supplies by building simplified, streamlined versions of the machines that require fewer parts and less time to make. This effort can help U.S. areas in need as well as under-served nations during the planet's time of need.
Great innovation and leadership, Ryan! We are always proud of your accomplishments and the great care which you provide our patients.
April 9, 2020
A big shout out to Angela Rogers (Senior Author), PACCM alumnus Kelly Vranas/Cardiology Fellow David Ouyong (Co-1st-authors) and super-mentor Michael Matthay (UCSF) on a likely-to-be-highly-cited-study in the April 1st issue of the American Journal of Respiratory and Critical Care Medicine.
As noted in the article "gender gaps exist in academic leadership positions and scholarly activities in critical care. Publication of peer-reviewed research is crucial to career advancement, and yet little is known about gender differences in authorship of critical care research."
"This study found that among more than 18,000 critical care clinical research and basic science studies published in 40 frequently cited journals between 2008 and 2018, women comprised 30.8% of first authors and 19.5% of senior authors, with minimal change over the last decade. When the senior author was female, the odds of female co-authorship rose substantially. However, compared with male first authors, female first authors tend to publish in lower-impact journals. These findings suggest factors that may contribute to the under-representation of women in academic leadership positions and scholarly activity in critical care, and they may help identify potential targets for improvement within the field"
This study is a clarion call for attention to the issue and reform.
Here is a link to the Blue Journal Study https://www.atsjournals.org/doi/pdf/10.1164/rccm.201910-1957OC
Congratulations to Angela, Kelly, David, Michael and their talented team of co-authors for an important study in the field!
March 31, 2020
It is with great sadness that we announce the passing of Dr. Chitra Dinakar, the Clinical Chief of Allergy, Asthma and Immunodeficiency in the PACCM Division. Chitra was a respected allergist, dedicated investigator, cherished mentor, beloved wife and treasured mother to two talented sons. She was the recipient of numerous awards that acknowledged her significant contributions to research, patient care and education. Earlier this month, we learned that Dr. Dinakar would be the recipient of The President’s Award from the American Academy of Allergy, Asthma and Immunology for her "significant contributions to the field of Allergy and Immunology as a clinician, a teacher, an author and as a role model for many AAAAI members.”
A more tangible symbol of Chitra's final months was the establishment of the The Stanford Adult Allergy, Immunodeficiency and Asthma Clinic which opened its doors in September of 2019; for this new enterprise, she recruited two skilled allergists, Priscilla Wong and Anna Arroyo, and guided them through the early months of the clinic's inception. While we are so proud of these accomplishments, it will be her warm and vibrant personality that we will remember most fondly.
Dr. Dinakar’s husband, Deendayal Dinakarpandian, is a data scientist with BMIR and we extend him, their sons, and all of Dr. Dinakar’s family and friends our deepest sympathy.
A private funeral service is being held because of the pandemic. People are welcome to leave comments at the following website: https://www.funeralcremation.com/obituary/chitra-dinakar
March 14, 2020
We are thrilled to announce that Dr. Yon Sung has won the 2020 Teaching Award for the Division of Pulmonary, Allergy and Critical Care Medicine.
As most of you know, Yon is an amazing clinician and a dedicated educator with special expertise in pulmonary hypertension.
A graduate of Pittsburgh Medical School, Yon did her IM residency at Brown before coming to Stanford for pulmonary training. With Roham Zamanian, she is our main right heart catheterization expert.
The consummate doctor, patient advocate and good-natured colleague, we are very proud of all the great work that Dr. Sung does at Stanford.
March 13, 2020
Congratulations to Dr. Chitra Dinakar, recipient of The President’s Award from the American Academy of Allergy, Asthma and Immunology for her "significant contributions to the field of Allergy and Immunology as a clinician, a teacher, an author and as a role model for many AAAAI members.”
(The award was scheduled to be announced at the Past Presidents & Honorary Award Recipients Luncheon in Philadelphia during the AAAAI Annual Meeting this month but is cancelled due to COVID-19.)
We are super proud of all the great accomplishments achieved by Chitra and send our good wishes to her with this happy announcement!
March 3, 2020
Congratulations to Dr. Kristina Kudelko who has been appointed as the PACCM Director of Clinical Educator Career Development and CE Track Fellows Curriculum, effective immediately. In this role, Kristina will devote her efforts to strengthen the CE faculty and fellows career pathways in an academic environment.
It is widely recognized that Dr. Joe Levitt and Dr. Angela Rogers, our leaders in fellowship training, as well as our UTL faculty, have done an amazing job to solidify the scientific and research successes of our fellows. This is evident with the consistent NIH fellowship awards and the number of fellows committing to research careers year after year. Likewise, Kristina will work with the clinically focused faculty to ensure their successes within Stanford, as well as preparing clinically aspiring fellows for careers in any academic institutions. With this appointment, we are excited and confident that our division will fulfill the core triple missions: research, teaching and clinical care.
Kristina completed her medical education at University of Pennsylvania, and residency/fellowship in PCCM at New York Presbyterian Hospital- Cornell. She completed the pulmonary hypertension fellowship at Stanford, and in 2010 joined the faculty of the division.
Kristina has been a stalwart of clinical teaching to trainees both in pulmonary hypertension and pulmonary consultative service. She is also a key leader responsible for educational curriculum of the PH fellowship.
Please join us in congratulating Kristina, and we look forward to the successes of this important initiative.
February 26, 2020
Tipping Point: The Resistance Is Gaining In The Lyme Wars, a Forbes article involving the latest research being done on Lyme disease by scientists, physicians and patient advocates all over the world, including our PACCM faculty member, Dr. Jayakumar Rajadas.
February 25, 2020
Congratulations to Dr. Arthur Sung, the new Senior Associate Chief for the Division of Pulmonary, Allergy and Critical Care Medicine.
Since returning to Stanford a few years ago to lead the new Interventional Pulmonary Program (now the busiest on the West Coast), Arthur's effect on the division has been absolutely transformational.
Because of his early leadership skills, he became the Associate Chief of Innovation and Strategy. In this role, he has been remarkable about putting the interests of others ahead of his own in developing their careers, especially junior faculty. He also brings a broad vision for how we can grow to be a leading division in the country by expanding our academic programs and clinical opportunities around the Bay Area.
January 17, 2020
A big congratulations to Dr. Sharon (Rebecca) Chinthrajah, who was selected as one of the top clinical research projects by The Clinical Research Forum for her study, “Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomized, double-blind, placebo-controlled, phase 2 study,” This study was chosen from an impressive field of applications and extremely qualified research programs. She was nominated by Dean Minor.
The award includes a presentation at the Translational Science 2020 conference in Washington DC in April, involves meetings with congressional offices at the annual “Hill Day” to promote the importance of funding for clinical research, and includes a travel award and formal recognition at the National Press Club in Washington D.C.
This is an important honor. We are proud of you, Sharon!
January 6, 2020
PACCM is very proud to announce that Dr. Vinicio de Jesus Perez and Dr. Tushar Desai were both elected into the American Society for Clinical Investigation (ASCI). The ASCI is an honor society of 3,000 physician-scientists from all medical fields. ASCI members are elected before their 50th birthday, and must demonstrate outstanding records of scholarly achievement in biomedical research. It is a signal achievement in the life of a physician-scientist.
Some facts from Wikipedia:
"The American Society for Clinical Investigation has its origins in a chance meeting in June 1907 on the Atlantic City boardwalk. The organization was also known as the "Young Turks" in allusion to the rebellious spirit in which it was founded, as a counterweight to the older and more deeply established Association of American Physicians (colloquially known as the "Old Turks" in subsequent years)."
"The ASCI includes physician-scientists who are active clinically, in basic research, or in teaching. Many of its senior members are widely recognized leaders in academic medicine. As of 2015 the membership of ASCI has included 417 members of the National Academy of Medicine, 191 members of the National Academy of Sciences, 40 Lasker Award winners, and 19 Nobel laureates."
"The ASCI supports the research into basic mechanisms and/or treatment of human diseases, and to the education of future generations of physician-scientists. The ASCI considers the nominations of several hundred physician-scientists from the United States and abroad each year and elects up to 80 new members each year for their significant research accomplishments relatively early in their careers."
We are very proud of you, Vinicio and Tushar!
December 20, 2019
Congratulations to Dr. Sharon (Rebecca) Chinthrajah! The Clinical Research Forum has selected her as a finalist for the 2020 Top 10 Clinical Research Achievement Awards for her study “Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomized, double-blind, placebo-controlled, phase 2 study”.
This nomination is a Top 20 nominated study, which is to say that this work was among the very best of a very large and competitive field of submitted articles. It is a high honor and a remarkable accomplishment, given the level of quality, scientific rigor and innovation in this year’s batch of nominated studies. The final decision about the studies receiving the Top Ten Awards, and be honored at the Top Ten event in Washington, D.C., will be made in January.
November 20, 2019
Please join PACCM in congratulating Dr. Ke Yuan who has been promoted to Assistant Professor of Medicine at the Boston's Children's Hospital starting December 1, 2019. The Boston Children's hospital is the nation's #1 pediatric hospital and one of the top research programs in cardiopulmonary disorders in the world. Ke will join Harvard faculty as a tenure track translational investigator whose work will center on understanding the role of pericytes in the establishment of pulmonary muscularization associated with congenital heart disease associated PH.
November 1, 2019
Our Division is working with Grace Anne Dorney and Ted Koppel (Dorney-Koppel Foundation) to develop COPD care and research at Stanford. Grace Anne just sent us this video, edited for Stanford, to help spearhead the campaign. COPD is the 3rd leading killer among chronic diseases.
October 18, 2019
We want to announce two big changes at Santa Clara Valley Medical Center: the retirement of Division Chief Dr. Carl Kirsch and the promotion of his replacement, Dr. Eric Hsiao. Since 1986, Carl has been a beloved teacher and an admired clinician to medical students, residents and fellows. Eric Hsiao is already well known to our pulmonary group at Stanford; we all look forward to his leading the next generation of lung physicians at the Valley. His new role as Division Chief at SCVMC is effective October 21, 2019. The pulmonary and critical care experience enjoyed by our trainees at the Valley is consistently considered among the very best experiences of the whole fellowship.
Congratulations to Drs. Carl Kirsch and Eric Hsiao!
October 15, 2019
"It is with great pleasure that we announce Dr. Meghan Ramsey will be a new MICU attending at Stanford Hospital. Meghan has long been passionate about the ICU. A Stanford IM Chief Resident, we were thrilled to recruit her into our group. She dedicated her third year of her PCCM fellowship to focus on ICU care delivery with CERC. Her teaching style, fellow advocacy, ability to work well with teams, clinical acumen, interest in quality improvement, and leadership skills will undoubtedly serve her well in her new role.
October 14, 2019
Early Monday morning, the 2019 Nobel Prize in Physiology or Medicine was awarded to three scientists who discovered how cells detect and respond to changes in oxygen levels.
There's a nice Stanford link to this prize: New Nobel laureate Gregg Semenza, MD, PhD, of the Johns Hopkins University School of Medicine, is collaborating with Stanford's Mark Nicolls, MD, on a way to use Semenza's prizewinning discovery to help lung transplant recipients.
"I was up at 5:30 a.m. emailing and congratulating Gregg," said Nicolls, describing his reaction to the Nobel Prize announcement. "I was absolutely thrilled. It was well deserved."
Lung transplants do not last as long as other solid-organ transplants, with only about half of recipients alive after five years. But a piece of research that evolved from the Nobel Prize discovery may help to change that.
Semenza's portion of the award recognized the discovery of HIF-1 alpha, a protein that switches genes on and off in response to low oxygen levels. This protein and its sister molecule, HIF-2 alpha, play important roles in maintaining the health of blood vessels. Loss of healthy blood vessels is a big contributor to failure of lung transplants.
Starting in 2011, Nicolls, a pulmonologist, and his Stanford team began publishing research with Semenza in which they increased HIF-1 alpha and HIF-2 alpha levels in animal models of lung transplant. When these proteins were more plentiful, the transplanted organs were healthier and lasted longer.
From that work, they've devised and patented a medication to turn up HIF-1 alpha levels. "It's a fluid that surgeons will apply to the transplanted lungs at the time of the operation to enhance natural blood vessel repair," Nicolls said. The treatment is in the process of being brought to market.
Nicolls and Semenza are figuring out how to apply the same principles to chronic lung transplant rejection.
"Lung transplant rejection is like a heart attack of the airways: You lose blood supply and get a scar, which turns into chronic rejection," Nicolls said, adding that chronic rejection is the No. 1 killer of lung transplant recipients. But turning up the HIF proteins can slow or reverse the process.
Semenza has been an important mentor and collaborator, Nicolls said, adding "He's a very generous but very careful and rigorous scientist."
And their findings illustrate the value of basic science, driven by curiosity rather than a particular goal. When Semenza first discovered HIF-1 alpha, he could not have guessed that the work might someday lead to longer-lasting lung transplants.
"When you learn how cells operate, the lessons can have very broad implications that only become apparent as years and decades go by," Nicolls said.
September 26, 2019
It's a real pleasure to announce a major NIH award to Joe Levitt, our talented ICU faculty member and Program Director for the PCCM Fellowship.
He will be leading the NIH/NHLBI ARREST Pneumonia Study, a 10-center, 600-patient clinical trial to validate the efficacy of inhaled corticosteroids and beta agonists for the prevention of lung injury and acute respiratory failure in patients hospitalized with pneumonia and hypoxemia.
This trial is a follow-up to the 60-patient trial published in Critical Care Medicine as part of Joe’s previous K23 Award. If successful, this trial has the potential to change management and improve outcomes of patients hospitalized with pneumonia, the leading infectious cause of hospitalization and death in the U.S.
The $7.7M award is a collaborative effort with Manisha Desai (Director of the Stanford Qualitative Science Unit which will serve as the data coordinating center) and Ken Mahaffey (Director of the Stanford Center for Clinical Research which will serve as the clinical coordinating center). Supporting this type of collaborative and impactful clinical research is precisely the mission of these important entities at Stanford.
With Angela Rogers (Associate Program Director for PCCM Fellowship and Internal Medicine Residency) and our peers in Anesthesia, Surgery, CV Surgery, Neurology and Emergency Medicine, Joe is helping, with this award, to build a prominent critical care research national presence at Stanford University.
September 24, 2019
Today, we learned that the request to change the division's name was approved by the School of Medicine.
The Division's name has been changed from ‘Pulmonary & Critical Care Medicine’ to ‘Pulmonary, Allergy & Critical Care Medicine’ and has been approved effective September 1, 2019.
This name change reflects several years of program building initiated by Dr. Kari Nadeau's transformative arrival to our Division, the establishment of the Sean N. Parker Center for Allergy and Asthma Research under Kari's leadership, and the recent opening of the Allergy, Asthma & Immunodeficiency Clinic in Atherton; the latter effort made possible by the tireless efforts of Dr. Chitra Dinakar.
Allergy is a truly interdisciplinary venture. We will work closely with our colleagues in Pediatrics, Immunology & Rheumatology, Otolaryngology Head & Neck Surgery, Infectious Diseases, GI and Cardiology to facilitate collaboration in both clinical care and research projects. We will work shoulder-to-shoulder with our friends in other divisions and departments.
September 16, 2019
Stanford Adult Allergy, Immunodeficiency and Asthma Clinic opens in Atherton Monday, September 16th, 2019.
We are proud to announce that the opening of the first free-standing Adult Allergy Clinic for Stanford University.
Working under the guidance of Dr. Chitra Dinakar, Clinical Chief of Allergy and the strong support of Stanford Health Care, Drs. Priscilla Wong and Anna Arroyo (our founding faculty for the clinic) have been working hard every day to prepare the clinic for its opening.
This initiative has its roots in Dr. Kari Nadeau coming into the the PCCM division several years ago.
Under Dr. Nadeau, the Sean N. Parker Center for Allergy and Asthma Research has performed transformative research in the field of food allergy.
PCCM will work collaboratively with our colleagues in Pediatrics, Rheumatology, and ENT to provide state-of-the-art care for patients suffering from allergy, immunodeficiency and asthma.
This clinic will also be a site for Allergy Fellow training.
A warm congratulations to the whole Allergy team - you all have worked spectacularly together over the last year to make this dream a reality, and the community will be your greatest beneficiaries.
September 13, 2019
Stanford's Medicine X program is advertised to be the 'world's leading program in health care innovation, patient engagement and emerging technologies.'
This year the conference focuses on solving the issue of curing and treating COPD and is being led by news celebrity Ted Koppel and Grace Anne Dorney Koppel (a COPD patient/advocate). Ted and Grace Anne are dedicated Stanford alumni. The event will be live-streamed. We are honored to have our faculty participating to represent Stanford as well as Divisional initiatives to tackle COPD care in the Bay Area.
'Stanford Medicine X is a multifaceted program that represents a new way of solving health care’s most pressing problems. Sown in the fertile soil of Stanford University’s rich academic resources; germinated at the grassroots level by passionate, imaginative people; nurtured in the high-energy, risk-taking environment of Silicon Valley, Medicine X is an innovative way of re-imagining digital health, medical education, clinical research, new health care venture formation, and more.'
Its attendees are designers, philanthropists and innovators looking for ways to creatively tackle society's unmet medical problems.
August 31, 2019
We are excited to report the official accreditation of The Stanford Hereditary Hemorrhagic Telangiectasia (HHT) Program as a Center of Excellence by the Cure HHT Foundation! Edda Spiekerkoetter will be the center director, and David Stevenson from LPCH Medical Genetics will be the associate director. The center will be administered and supported by the adult PCCM pulmonary vascular disease program. Over two years ago, Edda and David began the process of creating a multidisciplinary program which includes collaboration with medical genetics, interventional radiology, neurosurgery, ENT surgery, and support from hospital administration. In accrediting the program as a center of excellence, the Cure Foundation cited not only excellence in clinical care but specifically the existing research expertise of Stanford University as a major strength. Congrats to Edda and David!
June 18, 2019
Congratulations to Dr. Angela Rogers, winner of the 2019 McCormick Fellowship Award. This award was established to support the advancement of women in medicine and/or medical research directly, or by supporting the mentoring, training and encouragement of women pursuing the study of medicine, in teaching medicine, and engaging in medical research.
To all of you who work with and have been taught by Angela, you know how much she has contributed to our group since her arrival from Harvard a few years ago. As the Associate Director of the PCCM Fellowship and the Associate Program Director of the Department of Medicine Residency, she has had a truly transformative effect on the Division and Department while still managing to be a great intensivist and clinical researcher, a true role model.
May 31, 2019
We are pleased to announce that Dr. Joshua Mooney will be the new Associate Medical Director for Lung and Heart/Lung Transplantation at Stanford. Josh is a well-respected and thoughtful clinician who has made a significant contribution to our program as well as to the field. He has led a number of academic efforts to improve the allocation of organs to patients with advanced lung disease. He is beloved by his peers, patients, trainees and staff alike.
We have an incredibly busy and complex lung transplant program at Stanford. In addition to providing leadership help to Dr. Gundeep Dhillon (Medical Director), Josh will be guiding important quality initiatives in close coordination with SHC.
May 28, 2019
Congratulations to Lauren Eggert for her ATS Poster presentation, titled “Physicians May Be More Frequently Switching Biologics In Patients With Severe Asthma Who Have Problems With Initial Treatment, Research Indicate”, which made the ATS Morning Minute.
May 2, 2019
Dr. Mark Krasnow, the Executive Director of the Wall Center for Pulmonary Vascular Disease, has been recognized with one of the world's most distinguished honors, election into the National Academy of Sciences. The academy was created in 1863 to advise the nation on issues related to science and technology with scholars being elected after outstanding contributions to research. 2019 was a banner year for Stanford with four new members from the school of medicine being elected.
Mark , a Howard Hughes Medical Institute investigator, has trained a number of scientists who are now in prominent academic positions around the country. He uses genetic and genomic approaches to examine lung development and stem cells and the neural circuit of breathing. He has been an extremely effective leader of the Wall Center and has helped raise the national stature of our pulmonary programs. We are all super proud of Mark's latest recognition and are grateful for his ongoing leadership at the medical school.
April 26, 2019
Huge congrats to Paul Mohabir for again winning the The Arthur L. Bloomfield Award in Recognition of Excellence in the Teaching of Clinical Medicine! This award was established in recognition of Dr. Arthur L. Bloomfield’s reputation as a gifted teacher, and eligible recipients are individuals from the Stanford faculty who excel as teachers in clinical medicine. The Award recipients are recognized at the School of Medicine Commencement Ceremony. Dr. Mohabir has been recipient of numerous teaching awards including the Kaiser award which recognizes pre-clinical teaching.
April 26, 2019
A big congratulations to Nick Juul for his new NIH F32 award on lung aging and cancer! Nick is doing a great job under Tushar Desai's mentorship.
Well done, Nick!
April 22, 2019
A big congratulations to Professor Chitra Dinakar, Clinical Chief of Allergy at Stanford, for winning the American Academy of Pediatrics 2019 Jerome Glaser Award!
This award recognizes one outstanding pediatric allergist-immunologist in the nation for contributions in service, education, and as a clinician/teacher in Allergy and Immunology - a huge honor!
February 27, 2019
"Edda Spiekerkoetter, a pulmonary hypertension clinician-scientist, is the recipient of a new Department of Defense (DOD) grant addressing hereditary hemorrhagic telangiectasia (HHT), a condition associated with significant pulmonary vascular disease. This is a joint study with Dr. Spiekerkoetter serving as the principal investigator and Ross Metzger (Pediatric Cardiology), Astrid Gillich (Biochemistry) and David Stevenson (Medical Genetics), as co-investigators. Edda and colleagues are establishing a HHT Center of Excellence at Stanford, and this grant will be instrumental in supporting the basic research as well as clinical translational approaches for the new Center. Congratulations Edda and team!"
February 4, 2019
Dr. Ramon Ramirez III was awarded the best clinical abstract award at the 13th PVRI Annual World Congress on Pulmonary Vascular Disease in Barcelona, Spain. This meeting is the largest scientific meeting on the subject of pulmonary vascular diseases. Of a total of 300 abstracts, Ramon's work on prescription-based stimulants and risk of PAH was chosen to compete as an oral presentation and judged by key opinion leaders in the field. A big congrats to Ramon!
January 31, 2019
Congratulations to three new high impact publications in the Division!
Andrew Sweatt and colleagues published an exciting study using machine learning to classify patients with pulmonary arterial hypertension.1
Xinguo Jiang et al discovered a new survival molecule for airway blood vessels.2
Ke Yuan and co-authors evaluated pericyte changes in pulmonary arterial hypertension.3
1.Sweatt, A. J., Hedlin, H. K., Balasubramanian, V., Hsi, A., Blum, L. K., Robinson, W. H., Haddad, F., Hickey, P. M., Condliffe, R. A., Lawrie, A., Nicolls, M. R., Rabinovitch, M., Khatri, P., Zamanian, R. T. Discovery of Distinct Immune Phenotypes Using Machine Learning in Pulmonary Arterial Hypertension. Circ Res 2019 Jan 21. doi: 10.1161/CIRCRESAHA.118.313911
2. Jiang, X., Tian, W., Tu, A. B., Pasupneti, S., Shuffle, E., Dahms, P., Zhang, P., Cai, H., Dinh, T. T., Liu, B., Cain, C., Giaccia, A. J., Butcher, E. C., Simon, C., Semenza, G. L., Nicolls, M. R.Endothelial HIF-2alpha is Required for the Maintenance of Airway Microvasculature. Circulation 2019 Jan 22;139(4):502-517.
3. Yuan K, Shamskhou EA, Orcholski ME, Nathan A, Reddy S, Honda H, Mani V, Zeng Y, Ozen MO, Wang L, Demirci U, Tian W, Nicolls MR, de Jesus Perez VA.Loss of Endothelial Derived WNT5A is Associated with Reduced Pericyte Recruitment and Small Vessel Loss in Pulmonary Arterial Hypertension. Circulation 2018 Dec 11. doi: 10.1161/CIRCULATIONAHA.118.037642
January 30, 2019
Congratulations to Dr. Mark Nicolls and Amy Tian for being awarded a new $2.3M NIH R01 grant evaluating the role of inflammation in lymphedema. Together with Dr. Stan Rockson, the Nicolls' group recently published a study in the journal JCI Insight (October 2018) showing the effectiveness of anti-inflammatory therapy (ketoprofen) for this disease. Lymphedema is a chronic condition affecting hundreds of millions around the world. It is particularly troublesome to patients who have had lymph node resection for breast cancer and is caused by lymphatic obstruction which leads to disfigured and swollen extremities. Targeted anti-inflammatory therapy is a promising new approach for this disorder.
See our Grand Rounds, Core Lectures, Conferences, and more.
IASLC WCLC (World Conference on Lung Cancer): January 26-29, 2021: Singapore
American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting: February 26-March 1, 2021 (Virtually)
ISHLT Annual Meeting: April 27-30, 2021 (Virtually)
American Thoracic Society (ATS): May 14-19, 2021: San Diego, CA
Pulmonary Hypertension Association (PHA) Symposium: September 30-October 2, 2021: Arlington, VA
Aspen Lung Conference: June 9-12, 2021: Aspen, CO
North American Cystic Fibrosis (NACFC) Conference: September 30-October 2, 2021: San Antonio, TX